Smith & Nephew (LON:SN) Hits New 1-Year High – Should You Buy?

Smith & Nephew plc (LON:SN)’s share price hit a new 52-week high during mid-day trading on Friday . The company traded as high as GBX 1,293 and last traded at GBX 1,267, with a volume of 2148668 shares trading hands. The stock had previously closed at GBX 1,293.50.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Citigroup lifted their price objective on shares of Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the stock a “buy” rating in a research note on Friday, October 31st. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Smith & Nephew in a report on Friday, November 7th. Royal Bank Of Canada cut Smith & Nephew to a “sector perform” rating and cut their price target for the company from GBX 1,700 to GBX 1,350 in a research note on Wednesday, December 17th. Panmure Gordon restated a “hold” rating and set a GBX 1,200 price objective on shares of Smith & Nephew in a research note on Tuesday, December 9th. Finally, Berenberg Bank reiterated a “hold” rating and set a GBX 1,300 target price on shares of Smith & Nephew in a research report on Friday, January 23rd. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of GBX 1,381.33.

Smith & Nephew Price Performance

The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51. The company has a market cap of £13.89 billion, a price-to-earnings ratio of 45.62, a PEG ratio of 0.46 and a beta of 0.62. The business has a fifty day moving average price of GBX 1,234.95 and a 200 day moving average price of GBX 1,293.76.

Insider Activity at Smith & Nephew

In other news, insider Deepak Nath sold 1,240 shares of the stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of GBX 1,257, for a total value of £15,586.80. Company insiders own 0.19% of the company’s stock.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.